sarcosine has been researched along with Cancer of Prostate in 73 studies
cocobetaine: N-alkyl-betaine; cause of shampoo dermatitis
| Excerpt | Relevance | Reference |
|---|---|---|
| "Plasma sarcosine was measured using gas chromatography-mass spectrometry (GC-MS) in adults classified as noncancerous controls (with benign prostate hyperplasia [BPH], n = 36), with prostatic intraepithelial neoplasia (PIN, n = 16), or with PCa (n = 27)." | 7.96 | Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia. ( Appolonova, SA; Brito, A; Enikeev, DV; Fodor, M; Lartsova, EV; Lerner, YV; Lyundup, AV; Markin, PA; Mikhajlov, VY; Moskaleva, N; Potoldykova, NV; Shpot, YV, 2020) |
| "Plasma sarcosine was measured using gas chromatography-mass spectrometry (GC-MS) in adults classified as noncancerous controls (with benign prostate hyperplasia [BPH], n = 36), with prostatic intraepithelial neoplasia (PIN, n = 16), or with PCa (n = 27)." | 3.96 | Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia. ( Appolonova, SA; Brito, A; Enikeev, DV; Fodor, M; Lartsova, EV; Lerner, YV; Lyundup, AV; Markin, PA; Mikhajlov, VY; Moskaleva, N; Potoldykova, NV; Shpot, YV, 2020) |
| "Prostate cancer is the leading cause of cancer in men, and its incidence increases with age." | 2.82 | Dual contribution of the mTOR pathway and of the metabolism of amino acids in prostate cancer. ( Juárez-López, D; Schcolnik-Cabrera, A, 2022) |
| "Biomarkers can improve prostate cancer diagnosis and treatment." | 2.53 | Biomarkers in localized prostate cancer. ( Autorino, R; Bottero, D; Buonerba, C; Coman, I; Cosimato, V; De Cobelli, O; De Placido, S; Deliu, VM; Di Lorenzo, G; Ditonno, P; Ferro, M; Lucarelli, G; Perdonà, S; Terracciano, D, 2016) |
| "Prostate cancer is usually a disease of elderly men, however, over 40 years of age the tumor can appear at any times." | 2.50 | [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer]. ( Kovács, GL, 2014) |
| "Early diagnosis of cancer of the prostate is very important, because the sooner the cancer is detected, the better it is treated." | 2.49 | Sarcosine as a potential prostate cancer biomarker--a review. ( Adam, V; Babula, P; Cernei, N; Eckschlager, T; Gumulec, J; Heger, Z; Kizek, R; Masarik, M; Stiborova, M; Zitka, O, 2013) |
| "Prostate cancer is the most prevalent cancer in the Western male population and the second leading cause of cancer death in men, affecting over 10 million individuals." | 2.46 | Novel biomarkers and therapeutic targets for prostate cancer. ( Naz, RK; Williams, RM, 2010) |
| "Riboflavin was employed to mimic the active center of the enzyme sarcosine oxidase for constructing the biomimetic sensor." | 1.51 | An electrochemical sarcosine sensor based on biomimetic recognition. ( Chen, J; Fu, B; Li, K; Liu, T, 2019) |
| "Sarcosine is a widely discussed oncometabolite of prostate cells." | 1.48 | Sarcosine influences apoptosis and growth of prostate cells via cell-type specific regulation of distinct sets of genes. ( Adam, V; Buchtelova, H; Eckschlager, T; Heger, Z; Horackova, E; Michalek, P; Rodrigo, MAM; Stiborova, M; Strmiska, V, 2018) |
| "Post-treatment sarcosine levels were elevated in 266 (52%) patients and highly elevated (≥200 nmol/L) in 71 (13%) patients." | 1.48 | Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer. ( Adam, V; Cernei, N; Gumulec, J; Heger, Z; Lackova, Z; Pacik, D; Plevova, M; Raudenska, M; Sorokac-Kubolkova, A; Strmiska, V; Zitka, O, 2018) |
| "Prostate cancer is one of the most widespread types of tumor diseases in men." | 1.42 | On-line determination of sarcosine in biological fluids utilizing dummy molecularly imprinted polymers in microextraction by packed sorbent. ( Abdel-Rehim, A; Abdel-Rehim, M; Moein, MM, 2015) |
| "On this effort, prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine have been presented as promising tools." | 1.42 | Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine. ( Bottero, D; Bruzzese, D; Cosimato, V; De Cobelli, O; Ferro, M; Giorgio, E; Lucarelli, G; Marino, A; Mazzarella, C; Perdonà, S; Perruolo, G; Tagliamonte, V; Terracciano, D, 2015) |
| "Monitoring Prostate Cancer (PCa) biomarkers is an efficient way to diagnosis this disease early, since it improves the therapeutic success rate and suppresses PCa patient mortality: for this reason a powerful analytical technique such as electrochemiluminescence (ECL) is already used for this application, but its widespread usability is still hampered by the high cost of commercial ECL equipment." | 1.42 | An electrochemiluminescence-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer. ( Bertani, F; Biavardi, E; Dalcanale, E; Fracasso, G; Marcaccio, M; Paolucci, F; Prodi, L; Ramarli, D; Rampazzo, E; Valenti, G; Villani, E, 2015) |
| "Sarcosine has been investigated as a prostate cancer biomarker with mixed results concerning its predictive power." | 1.42 | A case control study of sarcosine as an early prostate cancer detection biomarker. ( Ankerst, DP; Hoefler, J; Leach, RJ; Liss, M; Thompson, IM; Zapata, D, 2015) |
| "Sarcosine, a potential biomarker of prostate cancer, has drawn great attention in recent years." | 1.40 | Sensitive determination of the potential biomarker sarcosine for prostate cancer by LC-MS with N,N'-dicyclohexylcarbodiimide derivatization. ( Chen, J; Chen, Z; Zhang, J; Zhang, W, 2014) |
| "As the prostate cancer (PCa) progresses, sarcosine levels increase both in tumor cells and urine samples, suggesting that this metabolite measurements can help in the creation of non-invasive diagnostic methods for this disease." | 1.40 | Sarcosine oxidase composite screen-printed electrode for sarcosine determination in biological samples. ( Costa-Rodrigues, J; Fernandes, MH; Noronha, JP; Pereira, CM; Rebelo, TS; Sales, MG; Silva, F, 2014) |
| "Metabolomic profiling of prostate cancer (PCa) progression identified markedly elevated levels of sarcosine (N-methyl glycine) in metastatic PCa and modest but significant elevation of the metabolite in PCa urine." | 1.39 | The role of sarcosine metabolism in prostate cancer progression. ( Asangani, IA; Ateeq, B; Athanikar, JN; Chinnaiyan, AM; Khan, AP; Mehra, R; Michailidis, G; Palapattu, G; Rajendiran, TM; Siddiqui, J; Sreekumar, A; Wei, JT; Yocum, AK, 2013) |
| "Moreover, patients with low grade prostate cancer had higher median SPON2 levels (p=0." | 1.39 | Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer. ( Battaglia, M; Bettocchi, C; Di Clemente, D; Ditonno, P; Galleggiante, V; Lucarelli, G; Palazzo, S; Rutigliano, M; Selvaggi, FP; Trabucco, S; Vavallo, A, 2013) |
| "Sarcosine was quantified using high-throughput liquid chromatography-mass spectrometry." | 1.39 | Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. ( Albanes, D; Andriole, G; Berndt, SI; Chu, LW; Fox, SD; Hoover, RN; Hsing, AW; Huang, WY; Issaq, HJ; Koutros, S; Meyer, TE; Veenstra, TD; Yu, K, 2013) |
| "Sarcosine has been identified as a differential metabolite that is greatly increased during progression from normal tissue to prostate cancer and metastatic disease." | 1.39 | Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer. ( Battaglia, M; Bettocchi, C; Ditonno, P; Fanelli, M; Galleggiante, V; Germinario, CA; Larocca, AM; Lucarelli, G; Maiorano, E; Rutigliano, M; Selvaggi, FP; Spilotros, M; Vavallo, A, 2013) |
| "Sarcosine oxidase was shown to eliminate only sarcosine in the presence of D,L-alanine, and was consequently used as the selective enzyme." | 1.39 | Partial enzymatic elimination and quantification of sarcosine from alanine using liquid chromatography-tandem mass spectrometry. ( Burton, C; Gamagedara, S; Ma, Y, 2013) |
| "• The prostate cancer cell lines PC-3, LNCaP and DU145 were cultured in media containing 4, 20 or 100 nm of folic acid and assayed for growth over 9 days by counting viable cells at 3-day intervals, or for invasion by passage through a Matrigel-coated transwell membrane." | 1.38 | Elevated physiological levels of folic acid can increase in vitro growth and invasiveness of prostate cancer cells. ( Bakkar, A; Bismar, TA; Brockton, NT; Liu, S; Petersen, LF; Weljie, AM; Wen, J, 2012) |
| "Sarcosine is reported to be a differential metabolite that is greatly increased during prostate cancer (PCa) progression." | 1.38 | Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. ( Battaglia, M; Bettocchi, C; Ditonno, P; Fanelli, M; Germinario, CA; Larocca, AM; Lucarelli, G; Rutigliano, M; Selvaggi, FP; Vavallo, A, 2012) |
| "Current prostate cancer (PCa) diagnosis based on prostate-specific antigen (PSA) has been gradually losing its credibility over the last decade due to contradictory results in published literature and clinical practice." | 1.38 | Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry. ( Chen, DD; Hewavitharana, AK; Hui, Y; Soliman, LC, 2012) |
| "Diagnosis of prostate cancer by prostate specific antigen (PSA) is error-prone and cannot distinguish benign prostatic hyperplasia (BPH) from malignant disease, nor identify aggressive and indolent types." | 1.38 | Plasma sarcosine does not distinguish early and advanced stages of prostate cancer. ( Bohm, L; Bouic, PJ; Fernandez, P; Harvey, J; Serafin, AM; Van der Watt, G, 2012) |
| "Sarcosine in prostate cancer tissue samples was recently reported to be increased during prostate cancer progression to metastasis and suggested to be a key metabolite of cancer cell invasion and aggressiveness." | 1.37 | Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. ( Bethan, B; Jentzmik, F; Jung, K; Kamlage, B; Kristiansen, G; Lein, M; Miller, K; Stephan, C, 2011) |
| "Sarcosine is an amino acid derivative of N-methylglycine and is involved in the amino acid metabolism and methylation processes that are enriched during prostate cancer progression." | 1.37 | Sarcosine as a marker in prostate cancer progression: a rapid and simple method for its quantification in human urine by solid-phase microextraction-gas chromatography-triple quadrupole mass spectrometry. ( Cavaliere, B; Macchione, B; Monteleone, M; Naccarato, A; Sindona, G; Tagarelli, A, 2011) |
| "Thus, sarcosine may induce prostate cancer progression by increased HER2/neu expression." | 1.37 | Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. ( Bouchelouche, K; Bouchelouche, P; Capala, J; Dahl, M; Kramer-Marek, G; Nordling, J, 2011) |
| "Sarcosine was suggested in a letter to Nature in 2009 as a biomarker for prostate cancer." | 1.37 | Is sarcosine a biomarker for prostate cancer? ( Issaq, HJ; Veenstra, TD, 2011) |
| "Sarcosine in urine was recently suggested to be a promising tool in prostate cancer (PCa) diagnostics." | 1.36 | Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. ( Erbersdobler, A; Jentzmik, F; Jung, K; Kristiansen, G; Lein, M; Miller, K; Schrader, M; Stephan, C, 2010) |
| "Among the metabolites in PCa bone metastases especially cholesterol was noted." | 1.36 | Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol. ( Antti, H; Bergh, A; Crnalic, S; Hörnberg, E; Johansson, AI; Moritz, T; Stattin, P; Surowiec, I; Thysell, E; Widmark, A; Wikström, P, 2010) |
| "Sarcosine levels were also increased in invasive prostate cancer cell lines relative to benign prostate epithelial cells." | 1.35 | Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. ( Ahsan, A; Alexander, DC; Beecher, C; Berger, A; Byun, J; Cao, Q; Cao, X; Chinnaiyan, AM; Ghosh, D; Han, B; Kalyana-Sundaram, S; Khan, AP; Laxman, B; Li, Y; Lonigro, RJ; Mehra, R; Nyati, MK; Omenn, GS; Pennathur, S; Poisson, LM; Rajendiran, TM; Shuster, JR; Sreekumar, A; Varambally, S; Wei, JT; Yu, J, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (8.22) | 29.6817 |
| 2010's | 60 (82.19) | 24.3611 |
| 2020's | 7 (9.59) | 2.80 |
| Authors | Studies |
|---|---|
| Ünlüer, ÖB | 1 |
| Altunkök, N | 1 |
| Özkütük, EB | 1 |
| Ersöz, A | 1 |
| Lin, X | 1 |
| Tian, M | 1 |
| Cao, C | 1 |
| Shu, T | 1 |
| Wen, Y | 1 |
| Su, L | 1 |
| Zhang, X | 2 |
| Schcolnik-Cabrera, A | 1 |
| Juárez-López, D | 1 |
| Delkov, D | 1 |
| Yoanıdu, L | 1 |
| Tomov, D | 1 |
| Stoyanova, R | 1 |
| Dechev, I | 1 |
| Uzunova, Y | 1 |
| Yamani, HZ | 1 |
| Safwat, N | 1 |
| Mahmoud, AM | 1 |
| Ayad, MF | 1 |
| Abdel-Ghany, MF | 1 |
| Gomaa, MM | 1 |
| Farokhi, S | 1 |
| Roushani, M | 1 |
| Saedi, Z | 1 |
| Markin, PA | 1 |
| Brito, A | 1 |
| Moskaleva, N | 1 |
| Fodor, M | 1 |
| Lartsova, EV | 1 |
| Shpot, YV | 1 |
| Lerner, YV | 1 |
| Mikhajlov, VY | 1 |
| Potoldykova, NV | 1 |
| Enikeev, DV | 1 |
| Lyundup, AV | 1 |
| Appolonova, SA | 1 |
| Rodrigo, MAM | 1 |
| Strmiska, V | 4 |
| Horackova, E | 1 |
| Buchtelova, H | 1 |
| Michalek, P | 3 |
| Stiborova, M | 6 |
| Eckschlager, T | 8 |
| Adam, V | 12 |
| Heger, Z | 11 |
| Wang, YZ | 1 |
| Ji, SY | 1 |
| Xu, HY | 1 |
| Zhao, W | 1 |
| Xu, JJ | 1 |
| Chen, HY | 1 |
| Pacik, D | 4 |
| Plevova, M | 3 |
| Urbanova, L | 1 |
| Lackova, Z | 3 |
| Necas, A | 1 |
| Narwal, V | 2 |
| Kumar, P | 3 |
| Joon, P | 1 |
| Pundir, CS | 3 |
| Wang, M | 1 |
| Zou, L | 1 |
| Liang, J | 1 |
| Wang, X | 1 |
| Zhang, D | 1 |
| Fang, Y | 1 |
| Zhang, J | 2 |
| Xiao, F | 1 |
| Liu, M | 1 |
| Gumulec, J | 6 |
| Raudenska, M | 2 |
| Sorokac-Kubolkova, A | 1 |
| Cernei, N | 7 |
| Zitka, O | 7 |
| Jaiwal, R | 1 |
| Guran, R | 2 |
| Krizkova, S | 2 |
| Vanickova, L | 1 |
| Klejdus, B | 1 |
| Tvrdikova, E | 1 |
| Keil, C | 1 |
| Haase, H | 1 |
| Liu, T | 2 |
| Fu, B | 1 |
| Chen, J | 4 |
| Li, K | 1 |
| Deswal, R | 1 |
| Skalickova, S | 1 |
| Sztalmachova, M | 1 |
| Rodrigo, MA | 1 |
| Sochor, J | 1 |
| Masarik, M | 8 |
| Hubalek, J | 1 |
| Trnkova, L | 1 |
| Kruseova, J | 1 |
| Kizek, R | 6 |
| Khan, AP | 3 |
| Rajendiran, TM | 3 |
| Ateeq, B | 1 |
| Asangani, IA | 1 |
| Athanikar, JN | 1 |
| Yocum, AK | 1 |
| Mehra, R | 3 |
| Siddiqui, J | 1 |
| Palapattu, G | 1 |
| Wei, JT | 3 |
| Michailidis, G | 1 |
| Sreekumar, A | 3 |
| Chinnaiyan, AM | 3 |
| Lucarelli, G | 5 |
| Rutigliano, M | 3 |
| Bettocchi, C | 3 |
| Palazzo, S | 1 |
| Vavallo, A | 3 |
| Galleggiante, V | 2 |
| Trabucco, S | 1 |
| Di Clemente, D | 1 |
| Selvaggi, FP | 3 |
| Battaglia, M | 3 |
| Ditonno, P | 4 |
| Koutros, S | 1 |
| Meyer, TE | 1 |
| Fox, SD | 1 |
| Issaq, HJ | 2 |
| Veenstra, TD | 2 |
| Huang, WY | 1 |
| Yu, K | 1 |
| Albanes, D | 1 |
| Chu, LW | 1 |
| Andriole, G | 1 |
| Hoover, RN | 1 |
| Hsing, AW | 1 |
| Berndt, SI | 1 |
| Spilotros, M | 1 |
| Fanelli, M | 2 |
| Larocca, AM | 2 |
| Germinario, CA | 2 |
| Maiorano, E | 1 |
| de Vogel, S | 1 |
| Ulvik, A | 1 |
| Meyer, K | 1 |
| Ueland, PM | 1 |
| Nygård, O | 1 |
| Vollset, SE | 1 |
| Tell, GS | 1 |
| Gregory, JF | 1 |
| Tretli, S | 1 |
| Bjørge, T | 1 |
| McDunn, JE | 1 |
| Li, Z | 2 |
| Adam, KP | 1 |
| Neri, BP | 1 |
| Wolfert, RL | 1 |
| Milburn, MV | 1 |
| Lotan, Y | 1 |
| Wheeler, TM | 1 |
| Green, T | 1 |
| Chen, X | 1 |
| Ryan, S | 1 |
| Asch, AS | 1 |
| Ruiz-Echevarría, MJ | 1 |
| Babula, P | 1 |
| Zhang, W | 1 |
| Chen, Z | 1 |
| Hrabec, R | 1 |
| Lan, J | 1 |
| Xu, W | 1 |
| Wan, Q | 1 |
| Lin, J | 1 |
| Rebelo, TS | 1 |
| Pereira, CM | 1 |
| Sales, MG | 1 |
| Noronha, JP | 1 |
| Costa-Rodrigues, J | 1 |
| Silva, F | 1 |
| Fernandes, MH | 1 |
| Kovács, GL | 1 |
| Moein, MM | 1 |
| Abdel-Rehim, A | 1 |
| Abdel-Rehim, M | 1 |
| Ferro, M | 2 |
| Bruzzese, D | 1 |
| Perdonà, S | 2 |
| Mazzarella, C | 1 |
| Perruolo, G | 1 |
| Marino, A | 1 |
| Cosimato, V | 2 |
| Giorgio, E | 1 |
| Tagliamonte, V | 1 |
| Bottero, D | 2 |
| De Cobelli, O | 2 |
| Terracciano, D | 2 |
| Kopel, P | 2 |
| Hodek, P | 1 |
| Valenti, G | 1 |
| Rampazzo, E | 1 |
| Biavardi, E | 1 |
| Villani, E | 1 |
| Fracasso, G | 1 |
| Marcaccio, M | 1 |
| Bertani, F | 1 |
| Ramarli, D | 1 |
| Dalcanale, E | 1 |
| Paolucci, F | 1 |
| Prodi, L | 1 |
| Ankerst, DP | 1 |
| Liss, M | 1 |
| Zapata, D | 1 |
| Hoefler, J | 1 |
| Thompson, IM | 1 |
| Leach, RJ | 1 |
| Buonerba, C | 1 |
| Deliu, VM | 1 |
| Autorino, R | 1 |
| Coman, I | 1 |
| De Placido, S | 1 |
| Di Lorenzo, G | 1 |
| Polanska, H | 3 |
| Ondrak, A | 1 |
| Skoda, J | 1 |
| Zitka, Z | 1 |
| Kumar, D | 1 |
| Gupta, A | 1 |
| Mandhani, A | 1 |
| Sankhwar, SN | 1 |
| Merlos Rodrigo, MA | 2 |
| Kulich, P | 1 |
| Vit, V | 1 |
| Abate-Shen, C | 1 |
| Shen, MM | 1 |
| Poisson, LM | 2 |
| Cao, Q | 2 |
| Yu, J | 2 |
| Laxman, B | 2 |
| Lonigro, RJ | 2 |
| Li, Y | 2 |
| Nyati, MK | 2 |
| Ahsan, A | 2 |
| Kalyana-Sundaram, S | 2 |
| Han, B | 2 |
| Cao, X | 2 |
| Byun, J | 2 |
| Omenn, GS | 2 |
| Ghosh, D | 1 |
| Pennathur, S | 2 |
| Alexander, DC | 2 |
| Berger, A | 2 |
| Shuster, JR | 2 |
| Varambally, S | 2 |
| Beecher, C | 2 |
| Couzin, J | 1 |
| Kuehn, BM | 1 |
| Darbon, JM | 1 |
| Jamaspishvili, T | 1 |
| Kral, M | 1 |
| Khomeriki, I | 1 |
| Student, V | 1 |
| Kolar, Z | 1 |
| Bouchal, J | 1 |
| Williams, RM | 1 |
| Naz, RK | 1 |
| Cao, DL | 2 |
| Yao, XD | 2 |
| Jentzmik, F | 2 |
| Stephan, C | 2 |
| Miller, K | 2 |
| Schrader, M | 1 |
| Erbersdobler, A | 1 |
| Kristiansen, G | 2 |
| Lein, M | 2 |
| Jung, K | 2 |
| Baum, CE | 1 |
| Price, DK | 1 |
| Figg, WD | 1 |
| Schalken, JA | 1 |
| Struys, EA | 1 |
| Heijboer, AC | 1 |
| van Moorselaar, J | 1 |
| Jakobs, C | 1 |
| Blankenstein, MA | 1 |
| Ghoshd, D | 1 |
| Hewavitharana, AK | 2 |
| Colleselli, D | 1 |
| Stenzl, A | 1 |
| Schwentner, C | 1 |
| Thysell, E | 1 |
| Surowiec, I | 1 |
| Hörnberg, E | 1 |
| Crnalic, S | 1 |
| Widmark, A | 1 |
| Johansson, AI | 1 |
| Stattin, P | 1 |
| Bergh, A | 1 |
| Moritz, T | 1 |
| Antti, H | 1 |
| Wikström, P | 1 |
| Wagner, C | 1 |
| Luka, Z | 1 |
| Kamlage, B | 1 |
| Bethan, B | 1 |
| Huang, CW | 1 |
| Cai, H | 1 |
| Shahinian, T | 1 |
| Conti, PS | 1 |
| Ye, DW | 1 |
| Zhu, Y | 1 |
| Zhang, HL | 1 |
| Wang, YX | 1 |
| Cavaliere, B | 1 |
| Macchione, B | 1 |
| Monteleone, M | 1 |
| Naccarato, A | 1 |
| Sindona, G | 1 |
| Tagarelli, A | 1 |
| Wu, H | 1 |
| Ma, C | 1 |
| Xue, R | 1 |
| Deng, C | 1 |
| Zeng, H | 1 |
| Shen, X | 1 |
| Dahl, M | 1 |
| Bouchelouche, P | 1 |
| Kramer-Marek, G | 1 |
| Capala, J | 1 |
| Nordling, J | 1 |
| Bouchelouche, K | 1 |
| Petersen, LF | 1 |
| Brockton, NT | 1 |
| Bakkar, A | 1 |
| Liu, S | 1 |
| Wen, J | 1 |
| Weljie, AM | 1 |
| Bismar, TA | 1 |
| Moazzami, AA | 1 |
| Zhang, JX | 1 |
| Kamal-Eldin, A | 1 |
| Aman, P | 1 |
| Hallmans, G | 1 |
| Johansson, JE | 1 |
| Andersson, SO | 1 |
| Soliman, LC | 1 |
| Hui, Y | 1 |
| Chen, DD | 1 |
| Bohm, L | 1 |
| Serafin, AM | 1 |
| Fernandez, P | 1 |
| Van der Watt, G | 1 |
| Bouic, PJ | 1 |
| Harvey, J | 1 |
| Burton, C | 1 |
| Gamagedara, S | 1 |
| Ma, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Uncovering the 'ORIGINS' of Diabetes[NCT02226640] | 80 participants (Actual) | Observational | 2010-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for sarcosine and Cancer of Prostate
| Article | Year |
|---|---|
Dual contribution of the mTOR pathway and of the metabolism of amino acids in prostate cancer.
Topics: Amino Acids; Arginine; Carbohydrates; Glutamine; Humans; Leucine; Lipids; Male; Proline; Prostatic N | 2022 |
Quantitative analysis of sarcosine with special emphasis on biosensors: a review.
Topics: Alzheimer Disease; Amino Acid Metabolism, Inborn Errors; Biomarkers; Biosensing Techniques; Colorect | 2019 |
Sarcosine as a potential prostate cancer biomarker--a review.
Topics: Biomarkers, Tumor; Chromatography, High Pressure Liquid; Databases, Factual; Glycine N-Methyltransfe | 2013 |
[New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Biopsy; Digital Rectal Examination; Early Detection of Cancer | 2014 |
Biomarkers in localized prostate cancer.
Topics: DNA Methylation; Early Detection of Cancer; Humans; Male; MicroRNAs; Oncogene Proteins, Fusion; Pros | 2016 |
Urine markers in monitoring for prostate cancer.
Topics: Annexin A3; Antigens, Neoplasm; Biomarkers, Tumor; Comparative Genomic Hybridization; Gene Fusion; G | 2010 |
Novel biomarkers and therapeutic targets for prostate cancer.
Topics: Anoctamins; Antigens, Neoplasm; Biomarkers, Tumor; Citric Acid; Endoplasmic Reticulum; Golgi Apparat | 2010 |
Advances in biomarkers for the early diagnosis of prostate cancer.
Topics: Antigens, Neoplasm; Biomarkers, Tumor; Early Diagnosis; Endoribonucleases; Glutathione S-Transferase | 2010 |
1 trial available for sarcosine and Cancer of Prostate
| Article | Year |
|---|---|
Nuclear magnetic resonance-based metabolomics enable detection of the effects of a whole grain rye and rye bran diet on the metabolic profile of plasma in prostate cancer patients.
Topics: 3-Hydroxybutyric Acid; Aged; Aged, 80 and over; Betaine; Cross-Over Studies; Diet; Homocysteine; Hum | 2011 |
64 other studies available for sarcosine and Cancer of Prostate
| Article | Year |
|---|---|
Graphenoxide Cross-Linker Based Potentiometric Biosensor Design for Sarcosine Determination.
Topics: Biosensing Techniques; Graphite; Humans; Male; Prostatic Neoplasms; Sarcosine | 2021 |
Using bimetallic Au/Cu nanoplatelets for construction of facile and label-free inner filter effect-based photoluminescence sensing platform for sarcosine detection.
Topics: Biomarkers, Tumor; Biosensing Techniques; Horseradish Peroxidase; Humans; Hydrogen Peroxide; Male; P | 2022 |
Oncometabolites in urine - a new opportunity for detection and prognosis of the clinical progress of verified prostate cancer-a pilot study.
Topics: Adult; Aged; beta-Alanine; Cross-Sectional Studies; Ethanolamines; Humans; Isoleucine; Kynurenine; M | 2022 |
Point-of-care diagnostics for rapid determination of prostate cancer biomarker sarcosine: application of disposable potentiometric sensor based on oxide-conductive polymer nanocomposite.
Topics: Biomarkers, Tumor; Humans; Male; Nanocomposites; Oxides; Point-of-Care Testing; Polymers; Prostate; | 2023 |
Fabrication of an electrochemical aptasensor for the determination of sarcosine based on synthesized CuCo
Topics: Aptamers, Nucleotide; Biosensing Techniques; Electrochemical Techniques; Humans; Male; Prostatic Neo | 2023 |
Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
Topics: Aged; Aged, 80 and over; Biomarkers; Biomarkers, Tumor; Biopsy; Gas Chromatography-Mass Spectrometry | 2020 |
Sarcosine influences apoptosis and growth of prostate cells via cell-type specific regulation of distinct sets of genes.
Topics: Apoptosis; Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Metasta | 2018 |
Bidirectional Electrochemiluminescence Color Switch: An Application in Detecting Multimarkers of Prostate Cancer.
Topics: 2,2'-Dipyridyl; Animals; Aptamers, Nucleotide; Biomarkers, Tumor; Biosensing Techniques; Colorimetry | 2018 |
Identification of Sarcosine as a Target Molecule for the Canine Olfactory Detection of Prostate Carcinoma.
Topics: Animals; Dogs; Feasibility Studies; Humans; Male; Prostatic Neoplasms; Sarcosine; Sensitivity and Sp | 2018 |
Fabrication of an amperometric sarcosine biosensor based on sarcosine oxidase/chitosan/CuNPs/c-MWCNT/Au electrode for detection of prostate cancer.
Topics: Biosensing Techniques; Chitosan; Copper; Dielectric Spectroscopy; Electrodes; Female; Gold; Humans; | 2018 |
The Urinary Sarcosine/Creatinine Ratio is a Potential Diagnostic and Prognostic Marker in Prostate Cancer.
Topics: Area Under Curve; Biomarkers, Tumor; Creatinine; Humans; Male; Middle Aged; Neoplasm Grading; Neopla | 2018 |
Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers; Humans; Male; Neoplasm Recurrence, Local; Posto | 2018 |
Construction and application of amperometric sarcosine biosensor based on SOxNPs/AuE for determination of prostate cancer.
Topics: Bacillus; Biosensing Techniques; Electrodes; Enzymes, Immobilized; Gold; Humans; Limit of Detection; | 2018 |
Sarcosine is a prostate epigenetic modifier that elicits aberrant methylation patterns through the SAMe-Dnmts axis.
Topics: Cell Line; CpG Islands; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Male; P | 2019 |
An electrochemical sarcosine sensor based on biomimetic recognition.
Topics: Biomarkers, Tumor; Biomimetic Materials; Biosensing Techniques; Chitosan; Electrochemical Techniques | 2019 |
Effect of sarcosine on antioxidant parameters and metallothionein content in the PC-3 prostate cancer cell line.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Free Radical Scavengers; Humans; Male; Metalloth | 2013 |
The role of sarcosine metabolism in prostate cancer progression.
Topics: Aged; Animals; Biomarkers, Tumor; Case-Control Studies; Cell Line, Tumor; Disease Progression; Gene | 2013 |
Spondin-2, a secreted extracellular matrix protein, is a novel diagnostic biomarker for prostate cancer.
Topics: Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Extracellular Matrix Proteins; Humans; Ma | 2013 |
Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Case-Control Studies; Early Detection of Cancer; Humans; | 2013 |
Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Castration; Disease-Free Survival; Docetaxel; Humans | 2013 |
Sarcosine and other metabolites along the choline oxidation pathway in relation to prostate cancer--a large nested case-control study within the JANUS cohort in Norway.
Topics: Betaine; Biomarkers, Tumor; Case-Control Studies; Choline; Chromatography, Liquid; Cohort Studies; G | 2014 |
Metabolomic signatures of aggressive prostate cancer.
Topics: Biomarkers, Tumor; Gas Chromatography-Mass Spectrometry; Humans; Male; Metabolomics; Neoplasm Gradin | 2013 |
TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells.
Topics: Antimetabolites, Antineoplastic; Carbon; Cell Proliferation; Cell Transformation, Neoplastic; Gene K | 2013 |
Sensitive determination of the potential biomarker sarcosine for prostate cancer by LC-MS with N,N'-dicyclohexylcarbodiimide derivatization.
Topics: Biomarkers; Chromatography, High Pressure Liquid; Dicyclohexylcarbodiimide; Humans; Isomerism; Male; | 2014 |
Determination of common urine substances as an assay for improving prostate carcinoma diagnostics.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Chromatography, Liquid; Disease Progress | 2014 |
Colorimetric determination of sarcosine in urine samples of prostatic carcinoma by mimic enzyme palladium nanoparticles.
Topics: Biomimetic Materials; Calibration; Colorimetry; Horseradish Peroxidase; Humans; Male; Metal Nanopart | 2014 |
Sarcosine oxidase composite screen-printed electrode for sarcosine determination in biological samples.
Topics: Biosensing Techniques; Electrodes; Enzymes, Immobilized; Humans; Hydrogen Peroxide; Limit of Detecti | 2014 |
On-line determination of sarcosine in biological fluids utilizing dummy molecularly imprinted polymers in microextraction by packed sorbent.
Topics: Adsorption; Automation; Biomarkers; Chromatography, High Pressure Liquid; Humans; Male; Molecular Im | 2015 |
Improving the prediction of pathologic outcomes in patients undergoing radical prostatectomy: the value of prostate cancer antigen 3 (PCA3), prostate health index (phi) and sarcosine.
Topics: Antigens, Neoplasm; Humans; Male; Prostatectomy; Prostatic Neoplasms; ROC Curve; Sarcosine | 2015 |
Paramagnetic nanoparticles as a platform for FRET-based sarcosine picomolar detection.
Topics: Antibodies, Monoclonal; Biomarkers, Tumor; Cell Line, Tumor; Dextrans; Fluorescence Resonance Energy | 2015 |
An electrochemiluminescence-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer.
Topics: Early Detection of Cancer; Electrochemical Techniques; Humans; Limit of Detection; Luminescence; Mal | 2015 |
A case control study of sarcosine as an early prostate cancer detection biomarker.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Early Detection of Cancer; Humans; Male; Middle Aged; Pr | 2015 |
Relation of exposure to amino acids involved in sarcosine metabolic pathway on behavior of non-tumor and malignant prostatic cell lines.
Topics: Amino Acids; Cell Line; Cell Line, Tumor; Cell Movement; Glycine N-Methyltransferase; Humans; Male; | 2016 |
Influence of Long-Distance Bicycle Riding on Serum/Urinary Biomarkers of Prostate Cancer.
Topics: Bicycling; Biomarkers, Tumor; C-Reactive Protein; Humans; Lactic Acid; Male; Middle Aged; Prostate-S | 2016 |
NMR spectroscopy of filtered serum of prostate cancer: A new frontier in metabolomics.
Topics: Aged; Biomarkers, Tumor; Biopsy; Citric Acid; Diagnosis, Differential; Digital Rectal Examination; G | 2016 |
Prostate tumor attenuation in the nu/nu murine model due to anti-sarcosine antibodies in folate-targeted liposomes.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationshi | 2016 |
Sarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Glyc | 2016 |
Diagnostics: The prostate-cancer metabolome.
Topics: Biomarkers; Humans; Male; Metabolome; Prostatic Neoplasms; Sarcosine | 2009 |
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.
Topics: Androgens; Cell Line; Cell Line, Tumor; Disease Progression; Gene Knockdown Techniques; Glycine N-Me | 2009 |
Biomarkers. Metabolite in urine may point to high-risk prostate cancer.
Topics: Biomarkers, Tumor; Humans; Male; Prostatic Neoplasms; Risk Factors; Sarcosine | 2009 |
Promising marker found for deadly prostate cancer.
Topics: Biomarkers, Tumor; Humans; Male; Prostatic Neoplasms; Sarcosine | 2009 |
[Analysis of the metabolome suggests a major potential role of sarcosine in the progression of cancer of the prostate].
Topics: Dimethylglycine Dehydrogenase; Disease Progression; Glycine N-Methyltransferase; Humans; Male; Metab | 2009 |
Beyond PSA: will future biomarker tests be better?
Topics: Biomarkers; Humans; Male; Mass Screening; Prostate-Specific Antigen; Prostatic Neoplasms; Sarcosine | 2009 |
Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours.
Topics: Aged; Biomarkers, Tumor; Cohort Studies; Creatinine; Digital Rectal Examination; Female; Humans; Mal | 2010 |
Sarcosine as a potential prostate cancer biomarker and therapeutic target.
Topics: Biomarkers, Tumor; Humans; Male; Prostatic Neoplasms; Sarcosine | 2010 |
Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development.
Topics: Biomarkers, Tumor; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Sarcosine | 2010 |
Serum sarcosine is not a marker for prostate cancer.
Topics: Biomarkers, Tumor; Humans; Male; Prostatic Neoplasms; Sarcosine | 2010 |
Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8.
Topics: Biomarkers; Digital Rectal Examination; Humans; Male; Prostatic Neoplasms; Sarcosine | 2010 |
Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8.
Topics: Biomarkers; Digital Rectal Examination; Humans; Male; Prostatic Neoplasms; Sarcosine | 2010 |
Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8.
Topics: Biomarkers, Tumor; Humans; Male; Prostatic Neoplasms; Sarcosine | 2010 |
Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.
Topics: Biopsy; Bone and Bones; Bone Neoplasms; Cholesterol; Computational Biology; Gas Chromatography-Mass | 2010 |
Sarcosine, folate metabolism and prostate cancer--is there a link?
Topics: Biomarkers, Tumor; Case-Control Studies; Folic Acid; Humans; Male; Neoplasm Invasiveness; Neoplasm S | 2011 |
Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.
Topics: Aged; Analysis of Variance; Biomarkers, Tumor; Biopsy, Needle; Cohort Studies; Diagnosis, Differenti | 2011 |
Biological stability evaluation of the α2β1 receptor imaging agents: diamsar and DOTA conjugated DGEA peptide.
Topics: Animals; Cell Line, Tumor; Copper Radioisotopes; Heterocyclic Compounds; Heterocyclic Compounds, 1-R | 2011 |
Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.
Topics: Aged; Aged, 80 and over; Algorithms; Antigens, Neoplasm; Biomarkers, Tumor; Case-Control Studies; Ea | 2011 |
Sarcosine as a marker in prostate cancer progression: a rapid and simple method for its quantification in human urine by solid-phase microextraction-gas chromatography-triple quadrupole mass spectrometry.
Topics: Adult; Gas Chromatography-Mass Spectrometry; Humans; Male; Prostatic Neoplasms; Sarcosine; Sensitivi | 2011 |
GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Gas Chromatography-Mass Spectrometry; Humans; Mal | 2011 |
Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells.
Topics: Androgens; Cell Line, Tumor; Cell Membrane; Cell Survival; Gene Expression Regulation, Neoplastic; H | 2011 |
Elevated physiological levels of folic acid can increase in vitro growth and invasiveness of prostate cancer cells.
Topics: Cell Proliferation; Folic Acid; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Sarcosine; | 2012 |
Is sarcosine a biomarker for prostate cancer?
Topics: Biomarkers, Tumor; Humans; Male; Prostatic Neoplasms; Sarcosine | 2011 |
Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy; Case-Control Studies; Dis | 2012 |
Monitoring potential prostate cancer biomarkers in urine by capillary electrophoresis-tandem mass spectrometry.
Topics: Adult; Biomarkers; Electrophoresis, Capillary; Humans; Isomerism; Male; Prostatic Neoplasms; Sarcosi | 2012 |
Plasma sarcosine does not distinguish early and advanced stages of prostate cancer.
Topics: Alanine; Biomarkers, Tumor; Gas Chromatography-Mass Spectrometry; Humans; Male; Neoplasm Staging; Pr | 2012 |
Partial enzymatic elimination and quantification of sarcosine from alanine using liquid chromatography-tandem mass spectrometry.
Topics: Alanine; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Humans; Male; Oxidatio | 2013 |